Novel and Practical Synthesis of Candesartan Cilexetil
摘要:
A novel and convergent synthetic route of candesartan cilexetil (API of Atacand), an effective angiotensin II receptor blocker, is described. Cleavage of the N-Boc and N-trityl protective group are implemented simultaneously and formation of the benzimidazole ring is conducted at the last step of this route, which gives candesartan cilexetil in 55% yield over six steps with 99.1% purity (HPLC).
[EN] A NEW PROCESS FOR THE PREPARATION OF CANDESARTAN CILEXETIL<br/>[FR] NOUVEAU PROCÉDÉ POUR LA PRÉPARATION DE CANDÉSARTAN CILEXÉTIL
申请人:FARMA GRS D O O
公开号:WO2015090635A1
公开(公告)日:2015-06-25
The present invention discloses the process for the preparation of candesartan cilexetil comprising the steps of hydrogenation of N02group of 1-(((cyclohexyloxy)carbonyl)oxy)ethyl 2-((tert-butoxycarbonyl)((2'-(1-tntyl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)amino)-3-nitrobenzoate by using a catalyst in an organic solvent, subsequent cleavage of the N-Boc group under acidic condition, followed by isolation of solid 1-(((cyclohexyloxy)carbonyl) oxy)ethyl 2-(((2'-(l H-tetrazol-5-yl)-[1,1'-bipheny|]-4-yl)methyl)amino)-3-aminobenzoate in the form of any pharmaceutically acceptable salt and ring closure by using tetraethyl orthocarbonate in an organic solvent to obtain the final product candesartan cilexetil.